NAME OF THE DRUG Isoniazid (INH) Antituberc ulars

DOSE/ ROUTE

INDICATION ACTION

SIDE EFFECTS

NURSES RESPONSIBILITY

300 mg First-line therapy of daily active tuberculosis, in com- bination with other agents. Prevention of tuberculosis in patients exposed to active disease (alone).

Bacteriocidal against rapidly dividing cells

Asymptomatic elevation of aminotransferas es, clinical hepatitis, fulminant hepatitis, peripheral neurotoxicity, hypersensitivity (skin rash, arthralgia, fever)

Mycobacterial studies and susceptibility tests should be performed prior to and periodically throughout therapy to detect possible resistance.

Hepatic

function

should

be

evaluated prior to and monthly throughout therapy. Advice patient to take

medication exactly as directed.if a dose is missed take as soon as possible. Emphasize the importance of continuing therapy even after symptoms have subsided. Advice patient to notify health care professional promptly if signs and symptoms of hepatitis. Caution patient to avoid the use of alcohol during the therapy

Rifampin (Rifadin) Antituberc ular.

600mg/d ay

Active tuberculosis (with other agents). Elimination of meningococcal carriers.

Bacteriocidal against rapidly dividing cells and against semidormant bacteria

Cutaneous reactions, GI disturbance (nausea, anorexia, abdominal pain), flulike syndrome, hepatotoxicity, immunologic reactions, orange discoloration of bodily fluids (sputum, urine, sweat, tears); drug interactions Perform mycobacterial studies and susceptibility test prior to and periodically during therapy to detect possible resistance. Assess lung sound and character and amount of sputum

periodically during therapy. Evaluate renal function, CBC, and urine analysis periodically. Monitor LFT.

Ethambutol 1 (Myambutol) daily antituberc ular

gm Active tuberculosis or Bacteriostatic other disease. mycobacterial tubercle bacillus

for

the Retrobulbar neuritis (decreased redgreen color discrimination), peripheral neuritis (rare), skin rash Evaluate renal function, CBC, and urine analysis periodically. Monitor LFT. Hepatic function should be

evaluated prior to and monthly throughout therapy. Advice patient to take

medication exactly as directed.if a dose is missed take as soon as possible.

DRUG NAME Pyrazinamide (PZA)

DOSE & ROUTE 1 gm daily Oral

ACTION Bacteriocidal effect against dormant or semidormant organisms

INDICATIONS Used in combination with other agents in the treatment of active tuberculosis.

SIDE-EFFECTS

NURSING RESPONSIBILITIES Emphasize the importance of continuing therapy

Hepatotoxicity, GI symptoms (nausea, vomiting), polyarthralgias, skin rash, hyperuricemia, dermatitis

even after symptoms have subsided. Advice patient to notify health care professional promptly if signs and symptoms of hepatitis. Caution patient to avoid the use of alcohol during the therapy Hepatic function should be evaluated prior to and monthly therapy. Advice patient to take medication exactly as directed. throughout

NAME OF THE DRUG tab.rantac (h2

DOSE/ ROUTE

INDICATION ACTION

SIDE EFFECTS

NURSES RESPONSIBILITY

150mg BD

Short-term treatment of active duodenal ulcers and benign gastric ulcers. Maintenance therapy for duodenal and gastric ulcers after healing of active Management ulcers. of

H2 receptor antagonist, it -none reported, blokes the histamine h2 other: headache, receptors , and prevents dizziness, rarely histamine mediated gastric hepatitis, acid secretion confusion, hypersensitivity

Assess for epigastric or abdominal pain and frank or occult blood in the stool, emesis, or gastric aspirate.

antagonists) Oral

-it should be given in empty stomach.

Watch reaction

for

any

allergic

GERD. Treatment of heartburn, indigestion. acid